How Boston Scientific Makes its Money: Revenue Breakdown
A breakdown of Boston Scientific (BSX) financials. See how Boston Scientific makes money from MedSurg (Endoscopy, Urology), Cardiovascular using their 2024 annual report.
How Does Boston Scientific Make its Money?
Boston Scientific is a global medical technology company that develops and markets devices used in interventional medical specialties. The company’s products span cardiovascular, rhythm management, endoscopy, urology, and neuromodulation. Boston Scientific has transformed itself over the past decade from a struggling device maker into one of the fastest-growing medtech companies, fueled by innovation in electrophysiology (FARAPULSE pulsed field ablation system), structural heart, and single-use endoscopy.
What separates Boston Scientific from competitors is its focus on minimally invasive, catheter-based procedures that replace open surgery. The company has deliberately avoided orthopedics and surgical robotics — areas dominated by Stryker and Intuitive Surgical — and instead doubled down on interventional cardiology, electrophysiology, and endoscopy where its engineering expertise gives it a durable edge. This strategy has paid off: Boston Scientific’s organic revenue growth has consistently outpaced the broader medtech industry since 2019.
Boston Scientific (BSX) Business Model
Boston Scientific Competitors
Boston Scientific’s key competitors and comparable public companies in the medical devices sector include Stryker, Intuitive Surgical, Abbott Laboratories, and Johnson & Johnson. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Boston Scientific stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| MedSurg (Endoscopy, Urology) | $5,400 | $4,800 | +12.5% |
| Cardiovascular | $10,500 | $8,900 | +18.0% |
| Total Revenue | $16,700 | $14,200 | +17.6% |
MedSurg (Endoscopy, Urology) — 32% of Revenue
The MedSurg segment encompasses Boston Scientific’s endoscopy and urology product lines. In endoscopy, the company sells devices used in gastrointestinal procedures — including biliary stents, tissue resection tools, and the EXALT single-use bronchoscope platform that eliminates cross-contamination risks from reprocessed scopes. The shift to single-use endoscopes has been a meaningful growth driver, as hospitals increasingly prioritize infection control following high-profile contamination events linked to reusable duodenoscopes.
The urology franchise includes products for kidney stone management (lithotripsy devices, ureteral stents), enlarged prostate treatment (the Rezūm water vapor therapy system), and pelvic health. Rezūm has been gaining share in the benign prostatic hyperplasia (BPH) market as an office-based alternative to traditional surgery. MedSurg revenue grew 12.5% in 2024, reflecting strong demand across both sub-segments and geographic expansion into emerging markets.
Cardiovascular — 63% of Revenue
Cardiovascular is by far the largest and fastest-growing segment, encompassing cardiology, electrophysiology, structural heart, peripheral interventions, and cardiac rhythm management. The headline story in 2024 was FARAPULSE, Boston Scientific’s pulsed field ablation (PFA) system for treating atrial fibrillation. PFA represents a generational shift in cardiac ablation — it selectively destroys heart tissue causing irregular rhythms while sparing surrounding structures like the esophagus and phrenic nerve. FARAPULSE has been gaining share rapidly since its U.S. launch, and the company believes PFA will expand the total addressable market by making ablation accessible to cardiologists who previously referred patients elsewhere.
The WATCHMAN left atrial appendage closure (LAAC) device is another major franchise, offering an alternative to lifelong blood thinners for atrial fibrillation patients. WATCHMAN generated strong double-digit growth as physician adoption expanded and next-generation devices improved procedural outcomes. The structural heart portfolio also benefits from transcatheter aortic valve replacement (TAVR) through the company’s ACURATE neo2 platform, primarily in Europe. Cardiovascular segment growth of 18% in 2024 was driven almost entirely by FARAPULSE adoption and WATCHMAN volume expansion.
Boston Scientific (BSX) Income Statement
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $16,700 | $14,200 |
| Cost of Revenue | $5,100 | $4,500 |
| Gross Profit | $11,600 | $9,700 |
| Operating Expenses | $7,200 | $6,300 |
| Operating Income | $4,400 | $3,400 |
| Net Income | $2,700 | $1,700 |
All values in millions USD unless otherwise stated.
Financial data sourced from Boston Scientific SEC Filings.
Boston Scientific (BSX) Key Financial Metrics
- Gross Margin: 69.5%
- Operating Margin: 26.3%
- Revenue Growth: 17.6%
Is Boston Scientific Profitable?
Yes, Boston Scientific is profitable and its earnings trajectory has been among the best in medtech. Net income jumped 59% to $2.7 billion in 2024, driven by both top-line growth and operating leverage. The 69.5% gross margin reflects the high-value nature of implantable medical devices — these are precision-engineered products sold to hospitals at premium prices, with substantial intellectual property protection. Operating margin expanded to 26.3% as revenue scaled faster than R&D and selling costs, though Boston Scientific continues to invest heavily in clinical trials and new product launches. The company’s free cash flow conversion has also improved, giving it flexibility for bolt-on acquisitions without excessive leverage.
Boston Scientific (BSX): What to Watch
- FARAPULSE market penetration — The pulsed field ablation system is still early in its U.S. launch. If PFA becomes the standard of care for atrial fibrillation ablation (replacing thermal ablation), the electrophysiology franchise could become Boston Scientific’s largest cardiovascular sub-segment within a few years.
- WATCHMAN competitive dynamics — Abbott’s Amulet LAAC device has received FDA approval and is competing directly with WATCHMAN. Market share shifts in this high-margin category will significantly impact cardiovascular segment profitability.
- Acquisition integration — Boston Scientific’s strategy relies on acquiring innovative smaller companies and scaling their technologies through its global distribution network. Recent deals need to deliver revenue synergies to justify the continued M&A pace.
- Single-use endoscopy transition — The shift from reusable to single-use endoscopes creates a recurring revenue opportunity but requires hospitals to accept higher per-procedure costs in exchange for infection prevention.
- International growth — Roughly 40% of revenue comes from outside the U.S. Regulatory approvals in China, Japan, and other large markets for FARAPULSE and next-generation devices represent a multi-year growth opportunity.
Boston Scientific (BSX) Financial Summary
Boston Scientific has emerged as one of medtech’s top growth stories, delivering 17.6% revenue growth in 2024 to reach $16.7 billion. The cardiovascular segment — led by the transformative FARAPULSE pulsed field ablation system and the WATCHMAN LAAC device — drove the majority of that growth at 18% year-over-year. The company’s 69.5% gross margins and expanding operating profitability (26.3% operating margin) reflect the premium pricing and clinical differentiation of its device portfolio. With net income surging 59% to $2.7 billion, Boston Scientific has the financial strength to sustain its aggressive innovation and acquisition strategy while rewarding shareholders.
Weekly Company Breakdowns — Visualized
See how top companies actually make money. Visual revenue breakdowns delivered free every week.